top of page
Search

NEW UPDATE: *Change in process for outpatient COVID-19 management*

To MUHC users: Please note that as of Dec 5, 2022, requests for outpatient antiviral management of COVID-19 for HIGH RISK patients should be directed to the ID-AMB (formerly MicroB/Lachine) service rather than ID-HOT. If a patient is a potential candidate for outpatient antiviral therapy but a delay is anticipated before they can be seen by Medical Day (eg. present to ED on a friday afternoon, weekend etc), please ensure that the antiviral is started in ED to ensure there are no delays in treatment! Prophylactic Evusheld should be offered to high-risk patients (see criteria) if > 6 months since their last dose.

 
 
 

Recent Posts

See All
New guide : IV to PO

The ASP committee is happy to make available the new guide IV to PO! It covers situation in which a switch to PO is indicated for certain...

 
 
 
We have a new look!

The MUHC ASP website has gone through a re-do: combination of spring cleaning and cosmetic changes, but keeping all the content! check...

 
 
 
Linezolid TDM

INESSS approved the TDM of Linezolid in May 2024 It is now available in the MUHC (via HSJ labs) The ASP committee is happy to publish a...

 
 
 

Comments


logo2.png

1001 Decarie Blvd, Montreal, Quebec H4A 3J1, Canada

+1 514-934-1934

bottom of page